INHIBITION OF DEGRANULATION OF POLYMORPHONUCLEAR LEUKOCYTES BY ANGIOGENIN AND ITS TRYPTIC FRAGMENT

Tschesche H, KOPP C, HORL WH, HEMPELMANN U (1994)
JOURNAL OF BIOLOGICAL CHEMISTRY 269(48): 30274-30280.

Download
No fulltext has been uploaded. References only!
Journal Article | Original Article | Published | English

No fulltext has been uploaded

Author
; ; ;
Abstract
A degranulation inhibiting protein was purified to apparent homogeneity from plasma ultrafiltrates of patients with uremia using gel-permeation chromatography, ion-exchange chromatography, affinity chromatography on blue Sepharose, and ion-exchange chromatography on a Mono S HR 5/5 fast protein liquid chromatography column. The identity of the isolated degranulation inhibiting protein with angogenin was demonstrated by amino acid sequence determination, immunoblotting, and identical inhibitory activity effects on leukocyte degranulation. At concentrations in the nanomolar range, the protein inhibited spontaneous degranulation of polymorphonuclear leukocytes (PMNL) to 40%. The protein discharge of cells, which were preincubated with nanomolar concentrations of angiogenin and then stimulated with the chemotactic peptide formyl-norleucyl-leucyl-phenylalanyl-norleucyl-tyrosyl-leucine (FNLPNTL), was inhibited by 70%. Cellular functions such as chemotaxis, phagocytosis, and the oxidative respiratory burst were not obviously affected by angiogenin. A polyclonal antibody to human recombinant angiogenin abolished the inhibitory effect of the isolated protein upon PMNL. The same but reduced effect was induced by the disulfide C-39-C-92 containing tryptic angiogenin fragment L-H-G-G-S-P-W P-P-C-92-Q-Y-R G-L-T-S-P-C-39-K, indicating a new, so far unknown biologically active site of angiogenin which is different from the sites responsible for angiogenic or ribonucleolytic activity. Two synthetic peptides containing residues 83-95, one with S-92 instead of C-92, revealed the same inhibitory effect on the protein degranulation of PMNL as the entire tryptic fragment.
Publishing Year
ISSN
PUB-ID

Cite this

Tschesche H, KOPP C, HORL WH, HEMPELMANN U. INHIBITION OF DEGRANULATION OF POLYMORPHONUCLEAR LEUKOCYTES BY ANGIOGENIN AND ITS TRYPTIC FRAGMENT. JOURNAL OF BIOLOGICAL CHEMISTRY. 1994;269(48):30274-30280.
Tschesche, H., KOPP, C., HORL, W. H., & HEMPELMANN, U. (1994). INHIBITION OF DEGRANULATION OF POLYMORPHONUCLEAR LEUKOCYTES BY ANGIOGENIN AND ITS TRYPTIC FRAGMENT. JOURNAL OF BIOLOGICAL CHEMISTRY, 269(48), 30274-30280.
Tschesche, H., KOPP, C., HORL, W. H., and HEMPELMANN, U. (1994). INHIBITION OF DEGRANULATION OF POLYMORPHONUCLEAR LEUKOCYTES BY ANGIOGENIN AND ITS TRYPTIC FRAGMENT. JOURNAL OF BIOLOGICAL CHEMISTRY 269, 30274-30280.
Tschesche, H., et al., 1994. INHIBITION OF DEGRANULATION OF POLYMORPHONUCLEAR LEUKOCYTES BY ANGIOGENIN AND ITS TRYPTIC FRAGMENT. JOURNAL OF BIOLOGICAL CHEMISTRY, 269(48), p 30274-30280.
H. Tschesche, et al., “INHIBITION OF DEGRANULATION OF POLYMORPHONUCLEAR LEUKOCYTES BY ANGIOGENIN AND ITS TRYPTIC FRAGMENT”, JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 269, 1994, pp. 30274-30280.
Tschesche, H., KOPP, C., HORL, W.H., HEMPELMANN, U.: INHIBITION OF DEGRANULATION OF POLYMORPHONUCLEAR LEUKOCYTES BY ANGIOGENIN AND ITS TRYPTIC FRAGMENT. JOURNAL OF BIOLOGICAL CHEMISTRY. 269, 30274-30280 (1994).
Tschesche, Harald, KOPP, C, HORL, WH, and HEMPELMANN, U. “INHIBITION OF DEGRANULATION OF POLYMORPHONUCLEAR LEUKOCYTES BY ANGIOGENIN AND ITS TRYPTIC FRAGMENT”. JOURNAL OF BIOLOGICAL CHEMISTRY 269.48 (1994): 30274-30280.
This data publication is cited in the following publications:
This publication cites the following data publications:

25 Citations in Europe PMC

Data provided by Europe PubMed Central.

Biochemical and Clinical Impact of Organic Uremic Retention Solutes: A Comprehensive Update.
Vanholder R, Pletinck A, Schepers E, Glorieux G., Toxins (Basel) 10(1), 2018
PMID: 29316724
Urinary Angiogenin Reflects the Magnitude of Kidney Injury at the Infrahistologic Level.
Tavernier Q, Mami I, Rabant M, Karras A, Laurent-Puig P, Chevet E, Thervet E, Anglicheau D, Pallet N., J Am Soc Nephrol 28(2), 2017
PMID: 27436854
Three decades of research on angiogenin: a review and perspective.
Sheng J, Xu Z., Acta Biochim Biophys Sin (Shanghai) 48(5), 2016
PMID: 26705141
The Ribonuclease A Superfamily in Humans: Canonical RNases as the Buttress of Innate Immunity.
Koczera P, Martin L, Marx G, Schuerholz T., Int J Mol Sci 17(8), 2016
PMID: 27527162
Angiogenin expression during early human placental development; association with blood vessel formation.
Pavlov N, Frendo JL, Guibourdenche J, Degrelle SA, Evain-Brion D, Badet J., Biomed Res Int 2014(), 2014
PMID: 25093183
The mammalian secreted RNases: mechanisms of action in host defence.
Gupta SK, Haigh BJ, Griffin FJ, Wheeler TT., Innate Immun 19(1), 2013
PMID: 22627784
Serum angiogenin levels are decreased in patients with psoriasis.
Miyagaki T, Sugaya M, Kamata M, Suga H, Morimura S, Tatsuta A, Uwajima Y, Yamamoto M, Shibata S, Fujita H, Asano Y, Kadono T, Sato S, Tada Y., Clin Exp Dermatol 37(7), 2012
PMID: 22439842
Angiogenin levels are increased in lesional skin and sera in patients with erythrodermic cutaneous T cell lymphoma.
Miyagaki T, Sugaya M, Suga H, Akamata K, Ohmatsu H, Fujita H, Asano Y, Tada Y, Kadono T, Sato S., Arch Dermatol Res 304(5), 2012
PMID: 22526325
Angiogenin, angiopoietin-1, angiopoietin-2, and endostatin serum levels in inflammatory bowel disease.
Oikonomou KA, Kapsoritakis AN, Kapsoritaki AI, Manolakis AC, Tiaka EK, Tsiopoulos FD, Tsiompanidis IA, Potamianos SP., Inflamm Bowel Dis 17(4), 2011
PMID: 20629092
Extracorporeal strategies for the removal of middle molecules.
Winchester JF, Audia PF., Semin Dial 19(2), 2006
PMID: 16551287
Angiogenin: a review of the pathophysiology and potential clinical applications.
Tello-Montoliu A, Patel JV, Lip GY., J Thromb Haemost 4(9), 2006
PMID: 16961595
Serum angiogenin in inflammatory bowel disease.
Koutroubakis IE, Xidakis C, Karmiris K, Sfiridaki A, Kandidaki E, Kouroumalis EA., Dig Dis Sci 49(11-12), 2004
PMID: 15628698
Angiogenin distribution in human term placenta, and expression by cultured trophoblastic cells.
Pavlov N, Hatzi E, Bassaglia Y, Frendo JL, Evain Brion D, Badet J., Angiogenesis 6(4), 2003
PMID: 15166501
An overview of uremic toxicity.
Vanholder RC, Glorieux GL., Hemodial Int 7(2), 2003
PMID: 19379356
Immunoglobulin light chains modulate polymorphonuclear leucocyte apoptosis.
Cohen G, Rudnicki M, Deicher R, Hörl WH., Eur J Clin Invest 33(8), 2003
PMID: 12864789
Natural inhibitors of neutrophil function in acute respiratory distress syndrome.
Geerts L, Jorens PG, Willems J, De Ley M, Slegers H., Crit Care Med 29(10), 2001
PMID: 11588452
Uremic toxicity: present state of the art.
Vanholder R, Argilés A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jorres A, Massy ZA, Rodriguez M, Stegmayr B, Stenvinkel P, Wratten ML., Int J Artif Organs 24(10), 2001
PMID: 11817319
Acquired disorders of phagocyte function complicating medical and surgical illnesses.
Engelich G, Wright DG, Hartshorn KL., Clin Infect Dis 33(12), 2001
PMID: 11698988
Neutrophil beta(2)-microglobulin and lactoferrin content in renal failure patients.
Deicher R, Exner M, Cohen G, Haag-Weber M, Hörl WH., Am J Kidney Dis 35(6), 2000
PMID: 10845826
Neutrophil function and infections in uremia.
Hörl WH., Am J Kidney Dis 33(2), 1999
PMID: 10023632

Export

0 Marked Publications

Open Data PUB

Web of Science

View record in Web of Science®

Sources

PMID: 7982938
PubMed | Europe PMC

Search this title in

Google Scholar